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Abstract
Background: Cigarette smoking affects the pharmacodynamic and pharmacokinetic behavior of many drugs and 
causes deterioration of pulmonary mechanics. We have evaluated the effect of cigarette smoking on washout time 
after one minimum alveolar concentration-h (1 MAC-h) of sevoflurane anesthesia.
Methods: We investigated the washout time of sevoflurane in 30 non-smoking and 30 healthy cigarette smoking (≥20 
cigarettes/day for>1 year) ASA I-II physical status patients, aged 18-63 years, who were candidates for 
otorhinolaryngologic elective surgery under 1MAC-h standardized sevoflurane anesthesia. At the end of the surgery, 
the sevoflurane vaporizer was turned off and the time taken for the sevoflurane concentration to decrease to MAC-
awake (0.3) and 0.1 MAC levels were recorded. In addition, the ratio of the fractions of inspired concentration (Fi) and 
expired concentration of sevoflurane (Fexp) at 1 MAC and Fexp of sevoflurane at 0.1MAC were recorded. The patients 
were mechanically ventilated during the washout time.
Results: We found no difference between the 2 study groups with regard to washout time of sevoflurane. The times of 
1MAC down to MAC-awake (106 ± 48 sec in non-smokers vs 97 ± 37 sec in smokers, p > 0.05) and down to 0.1MAC (491 
± 187 sec in non-smokers vs 409 ± 130 sec in smokers, p > 0.05) were similar. Similarly, there were no significant 
differences in the ratios of Fi/Fexp at 1MAC (1.18 in non-smokers vs. 1.19 in smokers, p > 0.05) and Fexp of sevoflurane 
at 0.1MAC (0.26 in non-smokers vs. 0.25 in smokers, p > 0.05).
Conclusions: Washout time of 1MAC-h sevoflurane anesthesia is not appear to be effected by cigarette smoking in 
patients without significant pulmonary disease.
Background
Cigarette smoking is a priority concern in perioperative
management [1-3] because it may promote local lung
inflammation that leads to lung dysfunction. Inhalation
of cigarette smoke promotes pulmonary inflammation by
inducing chemotaxis, retention, and activation of neutro-
phils and macrophages [4,5]. The inflammatory process is
probably essential for the development of lung injury and
in the ensuing impairment of lung function [6,7]. How-
ever, the pathologic response to cigarette smoke varies
among individuals [8].
Chronic exposure to cigarette smoke affects the metab-
olism of several drugs, including those anesthetics used
as muscle relaxants. Cigarette smoking may also affect
the sensitivity of the central nervous system to psychoac-
tive drugs, e.g. benzodiazepines and anesthetics [9,10].
Cigarette smoke contains over 4800 pharmacologically
active substances with chronic exposure producing mul-
tiple physiological effects. Cigarette smoking also affects
the pharmacodynamic and pharmacokinetic behavior of
many drugs. In addition, 5% inhaled sevoflurane in
humans is metabolized, predominantly by the cyto-
chrome P450 pathway (CYP2E1) induced by cigarette
smoking [11].
For these reason, the washout time of sevoflurane may
be disturbed in smokers. We have evaluated the effects of
cigarette smoking on the washout time after one mini-
mum alveolar concentration-h (1 MAC-h) sevoflurane
anesthesia.
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Methods
Patients
Having obtained the approval by the Local Ethics Com-
mittee and written informed consent, the study was con-
ducted by researchers among 60 American Society of
Anesthesiologists (ASA) physical status I or II patients
scheduled for otorhinolaryngologic surgery. We investi-
gated the washout time of sevoflurane in 30 life-long
non-smokers (never having smoked in their lives) and 30
cigarette smokers (≥20 cigarettes/day for>1 year)
patients. We assessed the two groups by via questioning
them and their relatives (wife, husband, mother, dad or
children). The patients were 18-63 years old, with body
mass indices ranging from 22 to 27. They were candidates
for otorhinolaryngologic elective surgery under 1MAC-h
standardized sevoflurane anesthesia. Patients with preex-
isting pulmonary failure, cardiac failure, hepatic failure,
renal failure or pulmonary hypertension and more 1 h-
long otorhinolayngologic elective surgical procedures
were excluded. All cigarette smokers were assessed for
pulmonary failure based on clinical assessment, blood gas
pressures, chest x-ray and pulmonary function tests.
Study design
Patients were not allowed to smoke the day of surgery.
Neither group received pre-medication. After being
taken to the operation room, all the patients were moni-
tored continuously throughout the study by standard
ASA monitors. In addition to standard ASA monitors,
inspired oxygen concentration (FiO2), inspired and
expired concentration of sevoflurane, and MAC levels of
the patients were monitored. An 18-gauge cannula was
inserted into the antecubital vein to infuse 0.9% NaCl
during surgery.
Anesthesia was induced by pentothal (5-7 mg.kg-1) and
fentanyl (1,5-2 μgr.kg-1). The patients' tracheas were intu-
bated by the application of rocuronium (0,6 mg.kg-1).
General anesthesia was maintained by remifentanyl infu-
sion (0,25-1 μg.kg-1.min-1) and sevoflurane. Fresh gas
flow was 4 lt.min-1. During general anesthesia, the end
tidal concentration of sevoflurane was maintained at 1
MAC (corrected for the patients' age). The duration of 1
MAC anesthesia of the operations was maintained for 1-
h. Patients were mechanically ventilated (VT: 6-8 ml. kg-1,
f: 12.min-1) adjusted to provide an end-tidal CO2 concen-
tration of 35-40 mmHg and SpO2 > 95% with 50% N2O in
oxygen, during the surgical procedures. The patients'
non-invasive arterial tension and heart rate were main-
tained within normal limits. All data were recorded on
each patient's observation chart.
At the end of the surgery, the sevoflurane vaporizer was
turned off and the time taken for the sevoflurane concen-
tration to decrease from 1MAC to 0.3 MAC (MAC-
awake) and 0.1 MAC were recorded. In addition, the ratio
of the fraction of inspired concentration (Fi) of sevoflu-
rane and of expired concentration (Fexp) of sevoflurane
at 1 MAC and Fexp of sevoflurane at 0.1MAC were
recorded. We measured the ratio of Fi/Fexp of sevoflu-
rane at 1MAC just before the sevoflurane vaporizer was
turned off. Because alterations of alveolar ventilation and
fresh gas flow would affect both the expired and inspired
sevoflurane concentrations at that time; the fresh gas
flows, tidal volumes and breathing frequency of the
patients were maintained at 6 lt. min-1, 6 ml. ideal kg-1
and 12 breath.min-1, respectively. Mechanical ventilations
of the patients were maintained until extubation and
standardized according to ideal body weight. All patients
were extubated after the last measurement.
Because it was considered unethical not to use any
agent in intubated patients at MAC-awake or 0.1 MAC,
we used remifentanil untill the patients' MAC values were
decreased to 0.1 MAC. Remifentanil infusion was
stopped when the 0.1 MAC level was reached.
Statistics
Statistical analysis was made by using the SPSS 15.0
(SPSS Inc., Chicago, IL) statistical program. Data were
expressed as mean ± SD. Statistical analysis utilized an
independent sample t-test for all variables. P < 0.05 was
considered significant. We estimated that a group of at
least 30 patients was adequate for parametric indepen-
dent sample t-test.
Results
Body mass index, age, weight and sex were similar in the
smoker and non-smoker groups (Table 1). We found no
significant differences between the 2 study groups
regarding the washout time of sevoflurane. The times
from 1MAC down to MAC-awake (106 ± 48 sec in non-
smokers vs. 97 ± 37 sec in smokers; p = 0.67) and
0.1MAC (491 ± 187 sec in non-smokers vs. 409 ± 130 sec
Table 1: Characteristics of the patients.
Smoker Non-smoker p
BMI 25.62 ± 2.2 26.57 ± 3.4 0.34
Age (years) 40 ± 10 42 ± 10 0.43
Weight 74.3 ± 11.23 77.07 ± 7.65 0.34
Sex 18 F, 12 M 17 F, 13 M 0.42
Body mass index (BMI), age, weight and gender of the groups are 
presented.
Statistical significant is presented as p value. F: female, M: male.Adanir et al. BMC Anesthesiology 2010, 10:8
http://www.biomedcentral.com/1471-2253/10/8
Page 3 of 5
in smokers, p = 0.08) were similar (Figs. 1 and 2). In addi-
tion, there was no significant difference in the ratios of Fi/
Fexp at 1MAC between non-smokers and smokers (1.18
vs. 1.19 at 1MAC respectively, p = 0.23) (Fig. 3). Fexp of
sevoflurane at 0.1MAC of the groups were also similar
(0.26 in non-smokers vs. 0.25 in smokers, p = 0.75) (Fig.
4).
Discussion
Mendonca et al. [12] found that inhalational induction
with sevoflurane was safe as an induction technique in 60
cigarette smokers. Similar to findings in other patient
groups, the use of a high initial concentration reduced
induction time. As inhalational induction time with sevo-
flurane is not affected by cigarette smoking, washout
time of 1MAC-h sevoflurane anesthesia also seems to be
uneffected by cigarette smoking in patients without sig-
nificant pulmonary disease.
Chronic exposure to cigarette smoke affects the metab-
olism of a number of drugs, including those used in anes-
thesia, e.g. muscle relaxants [13,14]. The
biotransformation of commonly used volatile agents is
primarily mediated by CYP2E1 and cigarette smoking
also induces this enzyme [11]. The CYP2E family con-
tains only one enzyme, CYP2E1 (previously known as
dimethylnitrosamine N-demethylase) which is responsi-
ble for the metabolism of small organic compounds, such
as alcohol and carbon tetrachloride as well as the haloge-
nated anesthetic agents halothane, enflurane, diethyl
ether, trichloroethylene, chloroform, isoflurane and
methoxyflurane [15,16]. Since sevoflurane is metabolized
by this pathway induced by cigarette smoke, there is the
possibility of a postoperative increase in serum inorganic
fluoride becomes exaggerated in smokers after the
administration of sevoflurane anesthesia. This was not
Figure 1 The time taken for sevoflurane concentration to de-
crease to 0.3 MAC (MAC-awake) (seconds).
Figure 2 The time taken for sevoflurane concentration to de-
crease to 0.1 MAC (seconds).
Figure 3 The ratio between inspired (Fi) and expired sevoflurane 
concentrations (Fexp) during surgery (Fexp/Fi) at 1 MAC.
Figure 4 The fraction of expired sevoflurane concentration 
(Fexp) at 0.1 MAC.Adanir et al. BMC Anesthesiology 2010, 10:8
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observed in a recent study, so there is no basis for clinical
concern [17].
Cigarette smoking may also affect the sensitivity of the
central nervous system to psychoactive drugs, such as
benzodiazepines and anesthetics. Lysakowski et al. [18]
found that higher doses of propofol were required to
abolish consciousness compared with non-smokers, sup-
porting the concept that cigarette smoking can alter cen-
tral nervous system sensitivity. These differences were
small, however, and unlikely to be of clinical significance.
Recovery from inhalational anesthesia depends on low-
ering the concentration of anesthetic in brain tissue.
Inhaled anesthetics are eliminated by biotransformation,
transcutaneous loss, and exhalation. Hepatic metabolism
of sevoflurane contributes approximately 5%, even when
cigarette smoking increases many-fold the function of the
P450 pathway, which is virtually considered quite low to
affect washout kinetics of this volatile agent. The most
important route for elimination of this inhalational anes-
thetic is through lung alveoli. Many of the factors that
speed induction also hasten washout time: elimination of
rebreathing, high fresh gas flow, low anesthetic-circuit
volume, low absorption by the anesthetic circuit,
decreased solubility, high cerebral blood flow, and
increased ventilation. The speed of washout time also
depends on the length of time the anesthetic has been
administered [19]. The alveolar ventilation, fresh gas flow
and length of time patients were anesthetized were kept
constant in our study. However, we found no statistically
significant differences between the groups for washout
time of sevoflurane. Although there seems to be a ten-
dency toward shorter washout times for the cigarette
smokers compared to the non-smokers, clinical signifi-
cance was not reached between the groups.
Active cigarette smoking also affects lung function
indices other than FEV1. In cigarette smokers, neutro-
phils are typically present in the lower airways. Cigarette
smoking is a known risk factor for acceleratingthe decline
of lung function in adults. Cigarette smoking has also
been associated with several diffuse lung diseases in
which both bronchiolar and interstitial lung inflamma-
tion seem to result from chronic cigarette smoke inhala-
tion [20]. An association between decrease in diffusion
capacity of the lung and cigarette consumption has been
observed, even in healthy subjects. Airway hyper-respon-
siveness also develops in cigarette smokers. We assumed
that washout time of inhaled anesthetics is affected
through all above results and can effect alveolar ventila-
tion.
Cigarette smoking increases hemoglobin, hemotocrit,
plasma fibrinogen, blood pressure and heart rate. It
seems to increase blood flow and the elimination of sevo-
flurane due to the induction of CYP2E1. On the other
hand, it seems to decrease the elimination of sevoflurane
via the lungs due to affect alveolar ventilation. However,
we did not observe any difference of washout time of
sevoflurane between the smokers and non-smokers in
our study.
Our results might have several limitations that deserve
comment. The study was conducted on a moderate sam-
ple size and our results may not apply to smokers with
lung disease. If we had obtained plasma levels of volatile
anesthetics, more accurate data might have been pro-
vided. We found no data evaluating washout time of
other volatile anesthetics in cigarette smokers. Further
studies are needed to evaluate washout time for more and
less soluble volatile agents in cigarette smokers.
Conclusions
Washout time of 1MAC-h sevoflurane anesthesia is not
effected by cigarette smoking in patients without signifi-
cant pulmonary disease.
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